- Prestige Consumer Healthcare to Release Fiscal 2025 First Quarter Earnings Results
- Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference
- Prestige Consumer Healthcare Inc. Reports Fiscal Year 2024 Results
- Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarter and Year-End Earnings Results
- Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag
- Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene
- Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter Earnings Results
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of Americaine® 20% Benzocaine Topical Anesthetic Spray Due to the Presence of Benzene
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder Due to the Presence of Benzene
More ▼
Key statistics
On Friday, Prestige Consumer Healthcare Inc (PBH:NYQ) closed at 70.68, -6.15% below its 52-week high of 75.31, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 71.02 |
---|---|
High | 71.78 |
Low | 70.38 |
Bid | 70.29 |
Offer | 71.06 |
Previous close | 70.40 |
Average volume | 237.23k |
---|---|
Shares outstanding | 49.68m |
Free float | 49.03m |
P/E (TTM) | 16.94 |
Market cap | 3.51bn USD |
EPS (TTM) | 4.17 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 21:10 BST.
More ▼